| Statement of Need |
Nocturia, or frequent urination at night time, is a common underreported urological disorder that is largely misunderstood in adults. Many patients see nocturia as a normal part of the aging process, and coping with the symptoms is common place. Nocturia has been reported to be the most bothersome of all urinary complaints and may have a role in numerous aspects of people's health and wellbeing, contributing to fatigue, depression, increased risk of heart disease, and, at times, traumatic injury through falls.
Normal frequency and volume for nocturnal urination have been poorly defined. With no accepted distinction between normal and abnormal urination, clinicians may overlook nocturia and the medical problems and conditions that are associated with it.
Identifying nocturia, determining its causes, and treating it effectively are key to improving a patient's quality of life. This Urology Circle activity will seek to define the terms associated with nocturnal voiding, review the pathophysiology of the noctura, identify the multifactorial risk factors that contribute to nocturia and discuss the role of pharmacotherapy in relieving symptom burden.
|
| Educational Method |
This activity will consist of didactic lectures and panel discussions supported by slides posted on the web.
|
| Method of Participation:
|
- Read the objectives and other introductory information.
- Listen to the audio while viewing the slides; please note that this program was recorded, and as a result, participants will not have the opportunity to ask questions of the presenter.
- Take the post-test.
- Complete the evaluation and registration information.
- Participants who complete the post-test and evaluation will be issued a CME certificate, which may be printed at their location. A database of certificates awarded online is maintained at the Dannemiller Foundation. No additional certificate will be mailed. If you have any questions, you may contact the Dannemiller Foundation at editor@dannemiller.com. Expiration date for credit is August 31, 2008.
- This activity should take about 1 hour to complete.
|
| Learning Objectives |
- Define the terms associated with nocturnal voiding and the place of nocturia in overactive bladder
- Review the pathophysiology of nocturia and identify the multifactorial risks associated with nocturia
- Discuss the role of pharmacotherapy to alleviate nocturia symptoms and increase patient satisfaction
|
| CME Accreditation |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Dannemiller Memorial Educational Foundation and The Customer Link, Inc. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.
The Dannemiller Memorial Educational Foundation designates this educational activity for a
maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
|
| Target Audience |
This activity is designed for urologists and primary care physicians with a special interest in urology. |
| Disclosures |
In accordance with the Accreditation Council for Continuing Medication Education (ACCME), the Dannemiller Memorial Educational Foundation requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest. Accordingly:
Dr. FitzGerald reported that she serves as a consultant for Merck & Co., Inc. and is a speaker for Medtronic, Inc. She also receives grant/research support from Astellas Pharma US, Inc. and Pfizer Inc.
Dr. Staskin reported that he serves as a consultant and speaker for Astellas Pharma US, Inc.; Esprit Pharma; Pfizer, Inc.; and Watson Pharmaceuticals, Inc. He also receives grant/research support from Esprit Pharma, Inc.and Watson Pharmaceuticals, Inc.
Jan Graham, medical writer, has no financial relationships with any commercial interests that are relevant to this activity to disclose.
The Dannemiller Memorial Educational Foundation staff that was involved in the development of this activity have no financial relationships with any commercial interests that are relevant to this activity. All staff of The Customer Link, Inc. involved in the development of this activity have no financial relationships to disclose.
To resolve identified conflicts of interest, the educational content was fully peer-reviewed by a physician member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
|
| Disclosure of Unlabeled or Investigational Drugs |
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
|
| Disclaimer |
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the Dannemiller Memorial Educational Foundation, Astellas Pharma US, Inc., or The Customer Link, Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
|
|
Jointly sponsored by Dannemiller Memorial
Educational Foundation This program is made possible by an educational grant from
and The Customer Link, Inc. Astellas Pharma US, Inc.
 |
